CRFS cases | Controls | ||||
---|---|---|---|---|---|
Treatment variable | Frequency | Percentage | Frequency | Percentage | p Value |
Conserving surgery | 31 | 69 | 40 | 58 | 0.24 |
Non-conserving surgery | 14 | 31 | 29 | 42 | |
Chemotherapy | 19 | 42 | 35 | 51 | 0.37 |
No chemotherapy | 26 | 58 | 34 | 49 | |
Radiotherapy | 39 | 87 | 51 | 74 | 0.10 |
No radiotherapy | 6 | 13 | 18 | 26 | |
Hormone therapy | 6 | 13 | 11 | 16 | 0.79 |
No hormone therapy | 39 | 87 | 58 | 84 | |
Lymph node positive | 17 | 38 | 17 | 25 | 0.13 |
Lymph node negative | 28 | 62 | 52 | 75 | |
Oestrogen receptor positive | 42 | 93 | 54 | 78 | 0.03 |
Oestrogen receptor negative | 3 | 7 | 15 | 22 | |
HER2 receptor positive | 6 | 13 | 8 | 12 | 0.78 |
HER2 Receptor negative | 39 | 87 | 61 | 88 |
CRFS, cancer-related fatigue syndrome.